Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The ECHO trial's long-term follow-up demonstrates that adding acalabrutinib to BR chemotherapy in frontline MCL not only improves progression-free survival but also drastically reduces the need for subsequent therapy. This challenges the common clinical practice of reserving potent BTK inhibitors for later lines of treatment.
Related Insights
Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.
Regimens like acalabrutinib plus venetoclax allow clinicians to start one drug and add the second months later. This flexibility accommodates patients' personal schedules, such as planned travel, making treatment initiation easier and improving the patient experience without compromising the regimen's core structure.
When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.
Despite advancements from first-generation (ibrutinib) to second-generation (acalabrutinib) BTK inhibitors, a consistent pattern emerges: the rate of complete responses plateaus around 36% over time. This suggests a potential biological limit for this class of drugs when used as monotherapy in CLL.
Early data from the CLL 314 study shows a progression-free survival benefit for pirtobrutinib over ibrutinib in frontline CLL patients. This finding suggests a potential future shift where non-covalent BTK inhibitors could become the initial standard of care.
The ECHO trial for older mantle cell lymphoma patients presents a clinical dilemma. Adding acalabrutinib to BR chemoimmunotherapy improved progression-free survival (PFS) but not overall survival (OS). This was because the reduction in lymphoma deaths was offset by an increase in fatal infections, creating a difficult risk-benefit discussion.
The landmark TRIANGLE trial has redefined frontline therapy for younger, fit mantle cell lymphoma patients. Adding a BTK inhibitor to induction and maintenance provides outcomes superimposable to those including an autologous stem cell transplant. This allows clinicians to omit the transplant, sparing patients significant toxicity without compromising efficacy.
The AMPLIFY regimen (acalabrutinib + venetoclax) has a built-in safety advantage. The initial two cycles of acalabrutinib monotherapy effectively debulk the disease, significantly reducing the risk of tumor lysis syndrome (TLS) when the potent BCL-2 inhibitor venetoclax is introduced later.
The primary goal in CML is evolving from chronic management to achieving Treatment-Free Remission (TFR). This paradigm shift favors using the most potent TKIs, like asciminib, first-line to induce deep, rapid molecular responses and enable eventual therapy discontinuation.
Clinical trials often mandate indefinite acalabrutinib treatment until progression. However, emerging data suggests Minimal Residual Disease (MRD) status could serve as a biomarker to guide de-escalation. Achieving MRD negativity may allow physicians to safely stop the BTK inhibitor, personalizing treatment duration to reduce toxicity and cost.